MRC2 and glioblastoma: Cancer cells positive for this receptor are dominant in sarcomas [11, 12], GBM [13, 14] and subtypes of AML [15], and uPARAP positive cell lines derived from these cancers were demonstrated to be sensitive in vitro to our uPARAP-directed ADC in a target receptor specific manner (Figure 4, Figure 5 and Table 1).